Business Context and Reporting Period
This Form 8-K Current Report was filed by ProMIS Neurosciences Inc. on July 6, 2022. The Company is incorporated in Canada and operates as an emerging growth company. The report details the approval of the Company's application to list its common shares on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Nasdaq Listing Approval: The Nasdaq Stock Market LLC approved the Company's application to list its common shares on The Nasdaq Capital Market.
- Trading Commencement: Common shares began trading on The Nasdaq Capital Market on July 8, 2022, under the symbol "PMN".
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The document serves solely to announce the regulatory approval for the stock exchange listing.
Investor Verification Checklist
- Verify the trading symbol "PMN" on The Nasdaq Capital Market starting July 8, 2022.
- Review the press release dated July 8, 2022 (Exhibit 99.1) for additional context on the listing.
- Confirm the Company's status as an emerging growth company for applicable accounting standard transitions.